The Latest
-
Getty Images
Too much of a good thing? A flood of data is slowing clinical trials.
Pharma companies want to know it all — but cutting out unnecessary data collection could speed drug R&D.
-
Getty Images
Ultra-rare diseases got a boost from recent FDA approval signalling more regulatory flexibility
Stealth BioTherapeutics’ FDA win could help build momentum in the broader rare disease space.
-
Getty Images
What a gene therapy win means for the Huntington’s disease pipeline
Recent results for a Huntington’s gene therapy confer a hopeful sign for R&D in the space.
-
Permission granted by Colossal Biosciences
Beyond dire wolves: Could Colossal’s de-extinction work transform human health?
While resurrected animal species grab headlines, Colossal’s behind-the-scenes R&D may be poised to make an impact for humans as well.
-
Chris Jackson/Getty Images via Getty Images
Nobel Prize victory spotlights immunology’s value in pharma
While saturated with mature blockbusters, the immunology space is vibrating with new potential breadwinners from the top companies.
-
Permission granted by Vertex Pharmaceuticals
Vertex’s quest for a breakthrough in Type 1 diabetes
The race is on for an insulin-producing treatment that doesn’t require immune suppressing drugs.
-
Ermath, Michael. (2020). "Individualized Therapies Workshop" [Photograph]. Retrieved from Flickr.
Dr. Peter Marks, former top FDA vaccine official, joins Eli Lilly
Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.
-
Getty Images
As setbacks plague other companies, MindMed becomes a front-runner in the psychedelics race
Challenges faced by other drugmakers have reinforced, rather than discouraged, MindMed’s approach to psychedelic drug R&D for anxiety and other disorders.
-
Permission granted by Teva
Q&AOvercoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’
In the three years since a leadership change, Teva has evolved its R&D approach beyond a long history making copycat medicines.
-
Win McNamee via Getty Images
Trump administration could lower drug prices by making other nations pay more
The Trump administration often touts its efforts to lower prices in the U.S. by matching what other countries pay, but there’s more to this policy story.
-
Leon Neal via Getty Images
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?
The only woman to head up a company in Big Pharma is stepping down from the role at the end of the year.
-
Jacob Bell/PharmaVoice
Takeda, in reversal, abandons cell therapy research
The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.
-
Courtesy of Merck
Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?
This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.
-
Getty Images
AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others
FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.
-
Getty Images
Top pharma industry conferences in 2026
Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.
-
Getty Images
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?
The new treatment may only offer modest benefits, but could gain traction in a market with few other options.
-
Getty Images
As obesity M&A heats up, pharmas could get ‘blinded by opportunity’
With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.
-
Getty Images
Is pharma’s IRA pricing battle running out of steam?
Despite recent court losses, the legal tides could still turn in the industry’s favor.
-
Sean Anthony Eddy via Getty Images
Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’
The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do the right thing” for the ecosystem and liquidate them, its executives say.
-
Dominik Bindl via Getty Images
Can a multibillion-dollar deal put Pfizer in the obesity big leagues?
After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.
-
Getty Images
Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach
Why multi-specific antibodies are seeing a fresh surge of industry buzz.
-
Getty Images
Q&ALilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics
The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.
-
Getty Images
With DTC ads under fire, pharma companies need to pivot
An executive order from HHS doesn’t prohibit direct outreach to consumers, but drugmakers will need to rethink their outreach strategies.
-
Getty Images
3 FDA approval firsts that could be around the corner
Several market-altering decisions are on the agency’s docket for the rest of 2025.
-
Getty Images
How pharma can play a role in the $1 trillion healthcare reinvention
A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.
